Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Outlook for 2025 to 2035

The benign prostatic hyperplasia (BPH) prostate treatment market is experiencing sustained growth driven by the rising prevalence of prostate-related disorders, increasing geriatric population, and continuous advancements in pharmacological and surgical interventions. Current market conditions reflect expanding adoption of effective drug therapies and minimally invasive procedures aimed at symptom relief and quality-of-life improvement. Growing healthcare expenditure and improved diagnostic awareness have enhanced early treatment rates across both developed and emerging markets.

Regulatory approvals of novel therapeutics and supportive reimbursement frameworks are contributing to greater accessibility and market confidence. The future outlook remains positive as technological innovations, including targeted drug formulations and laser-based procedures, are expected to enhance treatment outcomes.

Strategic collaborations among pharmaceutical companies and healthcare providers are strengthening the distribution network Overall, the market is positioned for consistent expansion supported by patient-centric product innovation, expanding healthcare infrastructure, and growing preference for non-surgical management options.

Quick Stats for Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

• Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Industry Value (2025): USD 34.2 billion
• Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Forecast Value (2035): USD 48.7 billion
• Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Forecast CAGR: 3.6%
• Leading Segment in Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market in 2025: BPH Drugs (61.4%)
• Key Growth Region in Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: North America, Asia-Pacific, Europe
• Top Key Players in Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Pfizer Inc., NxThera Inc., NeoTract Inc., Sanofi S.A, GlaxoSmithKline Plc., Allergan Plc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eli Lily & Company, Cardinal Health Inc.

Metric	Value
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Estimated Value in (2025 E)	USD 34.2 billion
Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Forecast Value in (2035 F)	USD 48.7 billion
Forecast CAGR (2025 to 2035)	3.6%

Segmental Analysis

The market is segmented by Treatment Type and Distribution Channel and region. By Treatment Type, the market is divided into BPH Drugs and BPH Devices. In terms of Distribution Channel, the market is classified into Institutional Sales, Retail Sales, and Online Pharmacies. Regionally, the market is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.

Insights into the Treatment Type Segment

The BPH drugs segment, holding 61.4% of the treatment type category, dominates the market due to its efficacy in symptom management and widespread physician preference for pharmacological therapy as the first line of treatment. Adoption has been reinforced by improved formulations of alpha-blockers and 5-alpha-reductase inhibitors that offer enhanced safety and tolerability.

The segment benefits from a broad patient base seeking non-invasive management and from consistent prescription volumes across both primary and specialty care settings. Competitive dynamics are supported by the introduction of combination therapies that provide better long-term relief and reduced recurrence.

Ongoing research into novel molecular targets is further diversifying the therapeutic landscape Accessibility through established retail and hospital pharmacies has sustained patient adherence rates, ensuring continued dominance of drug-based interventions within the overall BPH treatment ecosystem.

Insights into the Distribution Channel Segment

The institutional sales segment, accounting for 67.8% of the distribution channel category, leads the market due to the concentration of BPH treatments across hospitals, specialty clinics, and urology centers. Institutional procurement ensures bulk purchasing efficiency, consistent supply, and adherence to quality standards.

Adoption through institutional channels is supported by the presence of qualified specialists, comprehensive diagnostic facilities, and integrated care pathways that streamline treatment delivery. Strategic partnerships between healthcare institutions and pharmaceutical manufacturers have further optimized product availability and affordability.

The segment’s strength also lies in its ability to ensure continuous patient monitoring and follow-up care, enhancing overall treatment outcomes As healthcare infrastructure expands and institutional investments in urology services increase, this channel is expected to retain its dominant position and play a critical role in the long-term distribution strategy of BPH therapeutics.

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Insights

• Rising number of people suffering from benign prostatic hyperplasia and prostate problems in general is informing the growth in demand for the treatment.
• With growing preference towards minimally invasive surgeries, the demand for treatment procedures like transurethral needle ablation (TUNA) and prostatic urethral lift (PUL) is increasing.
• Increasing reputation of prostate artery embolization (PAE), due to its positive results, is helping the market’s growth.
• Innovations such as Optilume drug-coated balloon in benign prostatic hyperplasia (BPH) prostate treatment are aiding in the development of the market.
• Rise in the geriatric population is leading to an increase in patients with benign prostatic hyperplasia, expanding the scope of the market.

Trends in BPH Prostate Treatment Market

• Development of irregular eating habits due to the busy lifestyles of the youth is leading to an increase in BPH problems, necessitating the use of benign prostatic hyperplasia (BPH) prostate treatment.
• Increasing number of patients are opting for homeopathy and natural remedies for BPH and thus the market has multiple avenues for growth.
• Initiatives taken by governments to advance the healthcare system in their countries are creating a conducive environment for the market’s progress.
• Alpha blockers remain popular as a form of treatment for BPH and the continuing demand for the drugs is benefitting the market.
• Risk of side effects such as urinary tract infections and kidney damage limit the prospects of the market.
• High cost of BPH prostate treatment, especially those using devices, is set to hinder the growth of the market.
• Scientific skepticism over BPH home remedies and homeopathy solutions is set to restrict the growth of the market through those avenues.

Category-wise Outlook

Drugs continue to be the preferred treatment type for BPH. Institutional sales top the distribution channel segment.

Easy Administering Capabilities and Development of New Products Make Sure Drugs Remain the Predominant Treatment Type

For 2025, drugs are expected to account for 65.2% of the market share by treatment type. Some of the key drivers for the increasing use of drugs in BPH treatment are:

• Easy administration of drugs makes them popular as forms of treatment in the wider healthcare sector and that popularity is reflected in the benign prostatic hyperplasia (BPH) prostate treatment market.
• Development of drugs like tadalafil for BPH treatment, previously used exclusively to treat erectile dysfunction, is helping drugs to infiltrate further in the treatment of patients.

Attributes	Details
Top Treatment Type	Drugs
Market Share (2025)	65.2%

Increase in Research Related to Prostate-related Problems is Seeing Institutional Sales Grow

Institutional sales are anticipated to account for 64.7% of the market share in 2025. Some of the key drivers for the progress of institutional sales include:

• Research institutes are receiving funding from both the private and public sectors in an increasing manner. Thus, their buying capacity is increasing, and institutional sales of BPH treatment are growing.
• Proliferation of specialty clinics trading in minimally invasive surgeries is benefitting the development of institutional sales of BPH treatment.

Attributes	Details
Top Distribution Channel	Institutional Sales
Market Share (2025)	64.7%

Country-wise Analysis

The increasing geriatric population is contributing to the market’s acceleration in North America. The presence of a wide variety of treatments is also propelling the benign prostatic hyperplasia (BPH) prostate treatment industry in North America.

Advancement of research institutions is lending a helping hand to the progress of the market in the region. The focus on the technological development of healthcare companies in the region is making sure BPH treatment keeps up with the times in Europe.

Countries	CAGR
United States	4.0%
Canada	3.1%
United Kingdom	3.7%
France	3.3%
Italy	3.5%

Approval of New Treatment Methods Keeping Market Demand Flowing in the United States

The market is set to register a CAGR of 4.0% in the United States for the forecast period. The key drivers for growth are:

• Innovative treatment procedures for benign prostatic hyperplasia, such as the Optilume BPH catheter system, getting approvals at a faster rate is seeing the market develop positively in the United States.
• Transurethral resection of the prostate (TURP) remains ever-popular in the United States and thus the market is enjoying normal growth in the country.

Technological Advancement Informing Growth of the Market in Canada

The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in Canada is tipped to be 3.1% over the forecast period. Some of the key factors driving the growth are:

• Canadian companies are increasingly taking the help of technology and making the newest treatment forms available to consumers. Thus, the market is in for growth in the country.
• Irregular eating habits of a significant portion of Canadian consumers are leading to increased development of BPH patients in the country. Thus, BPH treatments are being sought in increasing measure in Canada.

Constant Innovation Through Research Affects Market Positively in the United Kingdom

The CAGR for the benign prostatic hyperplasia (BPH) prostate treatment market in the United Kingdom is tipped to be 3.7% over the forecast period. Some of the key factors driving the growth are:

• Research regarding BPH is being encouraged in the United Kingdom and the market is benefitting as a result. For example, in November 2025, the transurethral water-jet ablation treatment was made available country-wide in the United Kingdom after limited trials of five years.
• In January 2025, King Charles of the United Kingdom was affected by and underwent surgery for benign prostatic hyperplasia, raising the profile of BPH treatment in the country.

Governmental Concessions for BPH Treatment Sees the Market Enlarge in France

The market is expected to register a CAGR of 3.3% in France for the forecast period. Some of the key trends include:

• France’s government has taken steps to lower the cost of BPH treatment, which is helping the market’s cause in the country. For example, in March 2025, the Urolift implant procedure, courtesy of Teleflex Incorporated, was made reimbursable to patients above 50 years of age in France.
• Growing popularity of minimally invasive procedures in France sees BPH treatment of the minimally invasive nature progress in the country.

Development of New Supplements Freshening Up the Demand for BPH Treatment in Italy

The market is expected to register a CAGR of 3.5% in Italy over the forecast period. Some of the key trends include:

• Designing new supplements is aiding the market’s cause in Italy. For example, in 2025, trials found a whole tomato based food supplement eased the pain of men afflicted with benign prostatic hyperplasia in Italy.
• Rapidly aging population of Italy is developing prostate disorders at a greater rate and thus BPH treatment demand is increasing in the country.

Competitive Landscape in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

The benign prostatic hyperplasia (BPH) prostate treatment market is competitive, though a few companies are prominent in the market. One of the well-established companies in the market is Pfizer Inc., who are concentrated on expansion through its alpha-blockers range.

Other players in the market are implementing strategies such as acquisitions and mergers to get a competitive edge. Research and development are also given importance by these market players.

Recent Developments in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

• In May 2025, the English football club Sutton United was sponsored by Ideal Medical Solutions Ltd. The sponsorship aimed to raise awareness of the Elesta Echo-Laser treatment device for BPH.
• In February 2025, it was announced that the New Hall Hospital in Bodenham, England will receive equipment for the new ablation treatment procedure of BPH. The treatment uses imaging, robotics, and a heat-free water jet.
• In June 2025, the first BPH treatment with the iTind device was done in Canada by Olympus.

Key Companies in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market

• Pfizer Inc.
• NxThera Inc.
• NeoTract Inc.
• Sanofi S.A
• GlaxoSmithKline Plc.
• Allergan Plc.
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Eli Lily & Company
• Cardinal Health Inc.

Key Coverage in the Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Industry Report

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market Size and Share Analysis Global BPH Treatment Device Market Forecast BPH therapy market coverage Prostate enlargement treatment market assessment BPH medication market report Emerging trends in surgical BPH treatment analysis

Key Segments

By Treatment Type:

• BPH Drugs
  • Alpha Blockers
  • 5-Alpha Reductase Inhibitors
  • Phosphodiesterase-5 (PDE-5) Inhibitors
  • Muscarinic Receptor Antagonist (MRA)
  • Combination Drug
• BPH Devices
  • Prostatic Stents
  • Suture Base Implant Systems
  • Transurethral RF Thermal Therapy Devices

By Distribution Channel:

• Institutional Sales
  • Hospitals
  • Ambulatory Surgical Centres
  • Specialty Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)